Johnson Johnson MEDICAL DEVICES COMPANIES

The Future of Global Evidence Generation – Advancing the Role of Big Data in Innovation


Nicole Taylor Smith, JD Senior Director, Global Regulatory Affairs Policy and Intelligence Medical Devices Companies of Johnson & Johnson




RESTORE MORE



Integration of RWE into Total Product Life Cycle




Johnson-Johnson



Johnson-Johnson

Integration of RWE into the Total Product Life Cycle



Johnson-Johnson

Considerations and Challenges

- Access to Data
 - Technical Considerations/Barriers
 - Ownership
 - Health systems
 - Payors
 - Patient-generated health data
 - Infrastructure/Governance
 - Patient privacy
- Validation and Analytic Methods
- Security of data
- Global considerations

Striving for a Harmonization Approach

Benefits

- Leverage regional and global data to promote innovation
- Quicker dissemination of effective new therapies across regions
- Dramatically advance the ability to identify potential safety problems and respond more act to protect

Challenges

- Variation in regulatory requirements limiting the use of novel data and methods
- Legal restrictions
- Balancing the need to protect patient privacy and ensuring appropriate access to data
- Lack of consensus on shared and accepted analytical methods that are both nimble and reliable